Merrill keeps Actelion at neutral

Actelion Ltd. was retained at its neutral rating by Merrill Lynch analyst Erica Whittaker on stronger-than-expected Tracleer sales. Merrill increased its Tracleer sales forecasts for 2006 and 2007 by 5% and 7%. An increased diagnosis of pulmonary hypertension seems to be driving Tracleer sales. Shares of the Allschwil, Switzerland, biopharmaceutical company were down CHF 1.40, or 1.01%, at CHF 136.80 on volume of 220,015 shares versus the three-month running average of 155,155 shares. (Swiss: ATLN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.